Step Pharma is involved in the development of targeted oncology therapies for cancer treatment. The company is focused on the clinical development of its lead asset, dencatistat, a highly selective, orally bioavailable oncology drug for treating blood cancers and solid tumours.

Step Pharma

Step Pharma | 1,714 followers on LinkedIn. Developing selective inhibitors of CTPS1 for patients with cancer and auto-immune diseases | Step Pharma is the world leader in the discovery and development of inhibitors of CTPS1 (cytidine triphosphate synthase 1) for the treatment of cancer and autoimmune diseases. 
Step Pharma’s lead program dencatistat (STP938) is a first in class, potent, selective, oral inhibitor of CTPS1 with demonstrated anti-tumor activity. Dencatistat entered clinical development in 2022 in a PhI/II study for the treatment of relapsed and refractory T-cell and B-cell lymphoma.

Executive, Chairman, Entrepreneur

Erik van den Berg

CFO Step Pharma SAS

Nicolas Marsault

Chief Executive Officer at Step Pharma

Andy Parker

VP, Head of Clinical Operations at Step Pharma

Maureen Higgins

We’re working to stop the proliferation of malignant cancer cells in both blood cancers and solid tumours. Watch this short animation to learn about the potential of our unique and highly selective inhibitor, dencatistat, to address these high unmet medical needs. #CTPS1 #oncology #biotech #drugdiscovery

Our CEO Andy Parker will be attending #BIOEurope in Stockholm, Sweden, next week! Bio-Europe is the largest biopharma conference in Europe that provides a great opportunity to connect with industry leaders and potential partners spanning the global life science ecosystem. We are excited to connect with investors, partners, potential collaborators and fellow industry leaders, to explore the latest advancements of our lead candidate, dencatistat, and the exciting developments that lie ahead for Step Pharma. To arrange a meeting, please contact us via our website: Contact - Step Pharma ( step-ph.com ) We also thank the Auvergne-Rhone-Alps region for their support of Step Pharma. Find out more here: BIO-Europe | Meet dealmakers from biotech, pharma and finance ( informaconnect.com ) #bioeurope #biotech #CTPS1 #oncology #drugdiscovery

#ICYMI we recently shared our new animation demonstrating the innovative approach we are taking at Step Pharma to transform the cancer treatment landscape and bring better treatments to patients. Through our deep understanding of CTPS1 biology and nucleotide synthesis, Step Pharma has discovered dencatistat, a first-in-class, highly selective, orally bioavailable CTPS1 inhibitor. Watch the short animation to learn more about how this unique drug has the potential to revolutionise treatment for solid tumours and blood cancers. #CTPS1 #oncology #drugdiscovery

Do you know why Step Pharma is selectively targeting a key enzyme called cytidine triphosphate synthase 1 (CTPS1) for cancer? Watch this short video to learn why CTPS1 is regarded as cancer’s Achilles’ heel and a key target in the fight against blood cancers and solid tumours. #CTPS1 #oncology #drugdiscovery

💊 We are pleased to announce the publication of preclinical data from the University of Nantes in the HemaSphere Journal , further supporting the therapeutic potential of our highly selective and potent CTPS1 inhibitors in treating multiple myeloma, particularly in p53-deficient cases.💊 One of our CTPS1 inhibitors has shown strong synergy with drugs that inhibit ATR (key regulator of DNA damage response), offering a promising new strategy for patients with hard-to-treat multiple myeloma, where prognosis is poor and there is a need for new approaches. These findings provide further validation of the importance of inhibiting CTPS1 for the treatment of haematological malignancies that could potentially offer new and more effective treatment options for patients with blood cancers. Read the full paper here: https://lnkd.in/epg_NrUc #CTPS1 #Oncology #MultipleMyeloma #CancerResearch #HemaSphere

Our CEO Andy Parker , will be in San Francisco next week attending the BIO Investor Forum. Get in touch if you’re interested in discussing the latest developments with the world’s most advanced CTPS1 selective inhibitor, dencatistat, currently in clinical development for the treatment of blood cancers and solid tumors. At Step Pharma we are driving a step change in the treatment of cancer and working to revolutionize the treatment landscape. https://lnkd.in/egpuSMWf Find out more here: https://lnkd.in/dZf3Myxg #BIF2024 #CTPS1 #oncology #drugdiscovery

Our CSO Philip Beer will be presenting at the EORTC - European Organisation for Research and Treatment of Cancer , Cutaneous Lymphoma Tumour Group Annual Meeting 2024 in Lausanne, Switzerland. The EORTC meeting brings together exceptional oncology professionals worldwide, making connections and collaborating to find new solutions to change the treatment landscape of cutaneous lymphoma. We look forward to meeting investors, partners and potential collaborators to discuss the latest exciting developments around our lead candidate dencatistat and clinical development in lymphoma. To arrange a meeting, please contact us via our website: https://lnkd.in/egpuSMWf For more information, click here: https://www.eortc.org/ #CTPS1 #oncology #drugdiscovery

🎉 We are delighted to launch our new animation showcasing the groundbreaking work we’re doing in the fight against blood cancers and solid tumors! As the only company targeting cytidine triphosphate synthase 1 (CTPS1), the Achilles heel of cancer, Step Pharma is revolutionising the treatment landscape. Watch this short video to find out more about our lead CTPS1 selective inhibitor, dencatistat, and our breakthrough science. #CTPS1 #oncology #drugdiscovery

#ICYMI 🧬Our CEO Andy Parker recently shared a thought-provoking opinion piece in pharmaphorum , highlighting the game-changing role of genetics in cancer research and clinical trials. 🧬 He touched upon how integrating genetic insights into early drug development can significantly enhance treatment efficacy, improve regulatory outcomes, and boost investor confidence – especially crucial for single-asset companies. Read more about why Andy thinks that genetics could be the key to the future of cancer treatment and investment success. https://lnkd.in/ecV4NS2x #genetics #biotech #oncology #drugdiscovery #Pharma #Investment #Innovation

The genomics revolution is fundamentally changing the way cancer is diagnosed and treated, although progress has been centred around western populations. Our CSO, Philip Beer , is currently in Delhi with the Indian Cancer Genome Atlas (ICGA) Foundation , at a meeting dedicated to exploring ways to augment clinical diagnosis for Indian cancer patients as well as contributing to the Global Cancer Knowledge Base. Precision oncology will only truly succeed when the lives of all people living with cancer are impacted. #oncology #drugdiscovery #biotech

Metric
Company Name	Step Pharma
Symbol
MSH ID	COM:STEP-PH
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Pharmaceuticals
Country	FR
Stage
Employee Count
Website	step-ph.com
LinkedIn	step-pharma
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

STEP

COM:STEP-PH

Step Pharma

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue